[Ripretinib in the treatment of advanced gastrointestinal stromal tumor with metastases in liver, lung and bone: a case report]

Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):823-824. doi: 10.3760/cma.j.cn.441530-20210702-00255.
[Article in Chinese]

Abstract

报告1例男性、66岁的小肠胃肠间质瘤(GIST)伴肝、肺和骨转移患者的治疗经过。在先后经过口服伊马替尼400 mg/d、舒尼替尼37.5 mg/d、瑞戈非尼80 mg/d和120 mg/d以及放疗后,疾病仍在复发进展,并由单一的基因突变出现了复杂的基因复合突变。即选择瑞派替尼150 mg/d口服,7周后评效达部分缓解,表现为肺转移瘤较前明显退缩,其余病灶稳定或有不同程度缩小,治疗过程顺利,无药物相关性不良反应发生。.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Humans
  • Liver
  • Liver Neoplasms* / drug therapy
  • Lung
  • Naphthyridines / therapeutic use
  • Urea / analogs & derivatives

Substances

  • Antineoplastic Agents
  • Naphthyridines
  • Urea
  • ripretinib